Bionano Genomics (BNGO) Q1 2025 Earnings Call May 14, 2025 04:30 PM ET Company Participants David Holmes - Managing DirectorErik Holmlin - President and Chief Executive OfficerVidyun Bais - Equity Research - Vice PresidentJoanne Lee - Biotech Equity Research Associate Conference Call Participants Sung Ji Nam - Managing Director, Senior Equity Research Analyst Operator Good day, and welcome to the Bionana First Quarter twenty twenty five Earnings Conference Call. Today's conference is being recorded. At this ...

Codexis (CDXS) Q1 2025 Earnings Call May 14, 2025 04:30 PM ET Company Participants Carrie McKim - Director of Investor RelationsStephen Dilly - President, CEO & ChairmanStefan Lutz - Senior Vice President of ResearchGeorgia Erbez - Chief Financial OfficerTycho Peterson - Managing Director, Global EquitiesDan Arias - Managing Director Conference Call Participants Kristen Kluska - Equity Research AnalystAllison Bratzel - Senior Research AnalystMatthew Hewitt - Senior Research AnalystBrendan Smith - Director & ...

MDxHealth (MDXH) Q1 2025 Earnings Call May 14, 2025 04:30 PM ET Company Participants John Fraunces - DirectorMichael McGarrity - CEO & Executive DirectorRon Kalfus - Chief Financial OfficerNelson Cox - Equity Research Associate Conference Call Participants Andrew Brackmann - Research Analyst - HealthcareMark Massaro - MD & Senior Equity Research AnalystDaniel Brennan - Senior Equity Research Analyst - Managing DirectorJason Bednar - Senior Research AnalystThomas Vranken - Associate Director, Equity Research ...

BioRestorative Therapies (BRTX) Q1 2025 Earnings Call May 14, 2025 04:30 PM ET Company Participants Stephen Kilmer - Investor RelationsLance Alstodt - Chairman of the Board, President & CEORobert Kristal - CFOFrancisco Silva - Chief Scientist, VP of Research & Development, Secretary and DirectorJason Mccarthy - Senior Managing Director & Head of Biotechnology Research Conference Call Participants Jonathan Aschoff - Managing Director, Senior Research Analyst Operator Please note this conference is being reco ...

Financial Data and Key Metrics Changes - The company reported first quarter revenue of $84.6 million, representing a 3% year-over-year growth, with adjusted EBITDA of $14.7 million and an adjusted EBITDA margin of 17% [24][25][29] - Redemption revenue was $73.4 million, up 8% year-over-year, while third-party publisher redemption revenue increased by 38% year-over-year to $48.2 million [25][29] - Non-GAAP gross margin was 81%, down nearly 700 basis points year-over-year, primarily due to increased costs associated with Instacart and other publishers [28][29] Business Line Data and Key Metrics Changes - The company experienced a 37% year-over-year increase in total redeemers, reaching 17.1 million, driven by the launch of Instacart and Family Dollar [26] - D2C redemption revenue decreased by 24% year-over-year to $25.2 million, while ad and other revenues fell by 22% year-over-year to $11.2 million [25][29] - Redemptions per redeemer decreased by 15% year-over-year to 4.8, attributed to the growth in third-party redeemers [27] Market Data and Key Metrics Changes - The company is positioned to capture a greater portion of the $200 billion annual addressable spend in the U.S. CPG industry [21] - The company has seen significant growth in third-party redeemers, with a 45% year-over-year increase in redeemers on the third-party publisher network [61] Company Strategy and Development Direction - The company is focusing on establishing itself as the first true omni-channel performance marketing platform for the CPG industry, leveraging AI and performance marketing strategies [6][21] - The strategy includes handpicking a small number of industry thought leaders for pilot programs to refine product-market fit and scale operations [16][18] - The company aims to automate processes related to CPID (cost per incremental dollar) to enhance efficiency and expand client engagement [51][94] Management's Comments on Operating Environment and Future Outlook - Management noted that CPG companies are seeking new ways to drive incremental sales and are increasingly interested in credible measurement and performance marketing [6][10] - The company expects gradual increases in CPID-related contributions and improvements in sales execution, despite short-term supply constraints [31][32] - Management expressed confidence in the positive reception of initial CPID campaigns and the potential for significant revenue growth as clients embrace the platform [20][21] Other Important Information - The company ended the quarter with $297.1 million in cash and cash equivalents and repurchased 1.8 million shares at an average price of $39.47 [29][30] - The interim CFO, Valerie Shepherd, brings extensive financial leadership experience from Procter & Gamble, which is expected to benefit the company's financial strategy [22][23] Q&A Session Summary Question: Insights on Instacart integration and growth drivers - Management highlighted attractive redemption rates from Instacart and steady growth in redeemers, with plans to expand into new categories like alcohol [39][40] Question: Expansion of CPID and client engagement - Management noted that successful pilot programs have led to expanded brand participation, with a focus on building trust through credible measurement [48][49] Question: Outlook on CPG budgets and supply constraints - Management indicated that while macroeconomic factors create uncertainty, there is optimism about the ability to deliver incremental sales with credible measurement [59][63] Question: Publisher adaptations and redemption activity - Management reported improvements in the Walmart experience and ongoing enhancements to increase redemption activity across existing publishers [71][73] Question: Relationship between CPID penetration and supply growth - Management stated that while CPID penetration is a factor, improvements in sales execution will also contribute to increased supply of offers [75][76]

Forian (FORA) Q1 2025 Earnings Call May 14, 2025 04:30 PM ET Company Participants Max Wygod - Co-Founder, CEO, President & Executive Chairman of the BoardMike Vesey - Chief Financial Officer Conference Call Participants Richard Baldry - MD & Senior Research Analyst Operator Greetings, and welcome to Foran, Inc. First Quarter twenty twenty five Financial Results Conference Call and Webcast. At this time, all participants are in a listen only mode. A question and answer session will follow the formal comments ...

Financial Data and Key Metrics Changes - The company's net loss for Q1 2025 was $37 million, or $0.86 per share, compared to a net loss of $21.6 million, or $0.64 per share for Q1 2024 [20] - Non-GAAP adjusted net loss was $34.7 million, or $0.81 per share for Q1 2025, compared to a non-GAAP adjusted net loss of $19.9 million, or $0.59 per share for Q1 2024 [20] - Research and development expenses increased to $32.2 million for Q1 2025 from $20.6 million in Q1 2024, with a significant portion attributed to clinical trial activities [20][21] - General and administrative expenses rose to $3.9 million for Q1 2025 from $1.8 million in Q1 2024 [21] - Net cash used in operating activities was $35.9 million for Q1 2025, compared to $17.1 million for Q1 2024 [22] - The company ended the quarter with approximately $205.7 million in cash, cash equivalents, and short-term investments [22] Business Line Data and Key Metrics Changes - The company is focused on three clinical programs, with significant revenue potential if regulatory approvals are obtained [7][8] - The Phase III VICTORIA-one trial is designed to evaluate gadotelisib in combination with fulvestrant for advanced breast cancer patients [9] - The VICTORIA-two trial is a global Phase III study evaluating gadotelisib as a first-line treatment for HR positive, HER2 negative advanced breast cancer [15][16] - The Phase 1B2 trial is assessing gadotelisib in combination with darolutamide for metastatic castration-resistant prostate cancer [17] Market Data and Key Metrics Changes - The company estimates that nearly 200,000 late-stage cancer patients globally would be eligible for treatment with gadotelisib if approved [8] - The peak revenue potential for the second-line indication of gadotelisib could exceed $2 billion with just 40% market penetration [15] Company Strategy and Development Direction - The company aims to transition to a commercial stage company following potential FDA approvals for its clinical programs [10] - The focus is on developing effective therapies for advanced breast cancer patients resistant to endocrine therapy, addressing a significant unmet need in the market [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming clinical data readouts, with top-line data expected from the VICTORIA-one trial in Q3 2025 [7][10] - The company recognizes the importance of demonstrating clinically meaningful results in terms of progression-free survival (PFS) to gain market acceptance [12][14] Other Important Information - The company is collaborating with Dana Farber Cancer Institute and Massachusetts General Hospital to evaluate gadotelisib in endometrial cancer [18] - The company expects its current cash reserves to fund clinical development activities through 2026 [22] Q&A Session Summary Question: Timing for VICTORIA-one data readout - Management expects to lock the database in June and report results in Q3 2025, with no anticipated delays [27][28][30] Question: Impact of SERNA6 on second-line setting - Management believes SERNA6 will not affect their patient population as it pertains to first-line CDK4/6 patients [36][37] Question: Minimum HR for wild type update - Management indicated that an incremental three months in PFS would be considered clinically meaningful, but specifics will not be disclosed until data is available [39][40] Question: Change in timing for wild type readout - Management clarified that variability in event distribution among trial arms influenced the timing, but they remain confident in the Q4 timeline for the PIK3CA mutant population [43][44] Question: Prior proof of concept data for prostate cancer - Management discussed the encouraging non-clinical data supporting the efficacy of gadotelisib compared to single-node inhibitors [47][49]

Aytu Biopharma (AYTU) Q3 2025 Earnings Call May 14, 2025 04:30 PM ET Company Participants Robert Blum - Managing PartnerJosh Disbrow - Chief Executive OfficerRyan Selhorn - CFO Conference Call Participants Naz Rahman - Analyst Operator Please note this conference is being recorded. I will now turn the conference over to your host, Robert Blum, Investor Relations at Robert, your line, you may begin. Robert Blum Thank you very much, and good afternoon, everyone. As the operator indicated, during today's call, ...

Oncolytics Biotech (ONCY) Q1 2025 Earnings Call May 14, 2025 04:30 PM ET Company Participants Jon Patton - Director, IR & CommunicationWayne Pisano - Interim CEO & Chairman of the BoardThomas Heineman - Chief Medical OfficerChristophe Degois - VP, Business DevelopmentKirk Look - Chief Financial OfficerPatrick Trucchio - Managing Director Conference Call Participants Michael Freeman - Equity Research Analyst - Healthcare Operator Good afternoon, and welcome to OnClinic's Biotech's First Quarter Conference Ca ...

SeaStar Medical Holding (ICU) Q1 2025 Earnings Call May 14, 2025 04:30 PM ET Company Participants Jackie Cossmon - ConsultantEric Schlorff - CEOTim Varacek - SVP - Commercial & Business OperationsKevin Chung - Chief Medical OfficerDavid Green - CFONicholas Sherwood - Equity Research Associate Operator Hello, and thank you for standing by. My name is Tiffany, and I will be your conference operator today. At this time, I would like to welcome everyone to the SeaStar Medical First Quarter Financial Results Con ...